Skip to main content
PMC home page
Antimicrobial Agents and Chemotherapy logoLink to Antimicrobial Agents and Chemotherapy
. 1986 Dec;30(6):896–900. doi: 10.1128/aac.30.6.896

Pharmacokinetics of ticarcillin and clavulanic acid (timentin) in relation to renal function.

G L Jungbluth, D L Cooper, G D Doyle, G M Chudzik, W J Jusko
PMCID: PMC180615  PMID: 3492959

Abstract

The disposition of coadministered ticarcillin (3 g/1.73 m2) and clavulanic acid (100 mg/1.73 m2) was examined after a 30-min infusion in 24 noninfected subjects with various degrees of renal function. Noncompartmental pharmacokinetic parameters for the individual compounds were determined from plasma concentrations and urinary excretion rates. All clearances (total, renal, and nonrenal) and urinary recoveries of unchanged drug were found to be linearly related to creatinine clearance (CLCR). The steady-state volume of distribution (9.9 and 12.9 liters for ticarcillin and clavulanic acid) approximated the extracellular fluid space and was not related to CLCR. The half-lives increased with reduced renal function and ranged from 56 to 392 min for ticarcillin and 26 to 266 min for clavulanic acid. The clearances of both drugs decreased proportionately with reduction in renal function, facilitating dosing adjustments based on CLCR. Calculations of expected steady-state maximum and minimum concentrations in plasma using constant doses and an extended dosing interval related to CLCR further rationalized use of the 30:1 drug combination ratio for all patients.

Full text

PDF
896

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Bennett S., Wise R., Weston D., Dent J. Pharmacokinetics and tissue penetration of ticarcillin combined with clavulanic acid. Antimicrob Agents Chemother. 1983 Jun;23(6):831–834. doi: 10.1128/aac.23.6.831. [DOI] [PMC free article] [PubMed] [Google Scholar]
  2. Bodey G. P., Yeo E., Ho D. H., Rolston K., LeBlanc B. Clinical pharmacology of timentin (ticarcillin and clavulanic acid). Clin Pharmacol Ther. 1985 Aug;38(2):134–139. doi: 10.1038/clpt.1985.149. [DOI] [PubMed] [Google Scholar]
  3. Davies B. E., Coates P. E., Clarke J. G., Thawley A. R., Sutton J. A. Bioavailability and pharmacokinetics of clavulanic acid in healthy subjects. Int J Clin Pharmacol Ther Toxicol. 1985 Feb;23(2):70–73. [PubMed] [Google Scholar]
  4. Davies B. E., Humphrey M. J., Langley P. F., Lees L., Legg B., Wadds G. A. Pharmacokinetics of ticarcillin in man. Eur J Clin Pharmacol. 1982;23(2):167–172. doi: 10.1007/BF00545973. [DOI] [PubMed] [Google Scholar]
  5. Fuchs P. C., Barry A. L., Thornsberry C., Jones R. N. In vitro activity of ticarcillin plus clavulanic acid against 632 clinical isolates. Antimicrob Agents Chemother. 1984 Mar;25(3):392–394. doi: 10.1128/aac.25.3.392. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Hunter P. A., Coleman K., Fisher J., Taylor D. In vitro synergistic properties of clavulanic acid, with ampicillin, amoxycillin and ticarcillin. J Antimicrob Chemother. 1980 Jul;6(4):455–470. doi: 10.1093/jac/6.4.455. [DOI] [PubMed] [Google Scholar]
  7. Höffken G., Tetzel H., Koeppe P., Lode H. Pharmacokinetics and serum bactericidal activity of ticarcillin and clavulanic acid. J Antimicrob Chemother. 1985 Dec;16(6):763–771. doi: 10.1093/jac/16.6.763. [DOI] [PubMed] [Google Scholar]
  8. Janicke D. M., Cafarell R. F., Parker S. W., Apicella M. A., Jusko W. J. Pharmacokinetics of aztreonam in patients with gram-negative infections. Antimicrob Agents Chemother. 1985 Jan;27(1):16–20. doi: 10.1128/aac.27.1.16. [DOI] [PMC free article] [PubMed] [Google Scholar]
  9. Libke R. D., Clarke J. T., Ralph E. D., Luthy R. P., Kirby W. M. Ticarcillin vs carbenicillin: clinical pharmacokinetics. Clin Pharmacol Ther. 1975 Apr;17(4):441–446. doi: 10.1002/cpt1975174441. [DOI] [PubMed] [Google Scholar]
  10. Mangione A., Boudinot F. D., Schultz R. M., Jusko W. J. Dose-dependent pharmacokinetics of mezlocillin in relation to renal impairment. Antimicrob Agents Chemother. 1982 Mar;21(3):428–435. doi: 10.1128/aac.21.3.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
  11. Matzke G. R., Abraham P. A., Halstenson C. E., Keane W. F. Cefotaxime and desacetyl cefotaxime kinetics in renal impairment. Clin Pharmacol Ther. 1985 Jul;38(1):31–36. doi: 10.1038/clpt.1985.130. [DOI] [PubMed] [Google Scholar]
  12. Neu H. C., Garvey G. J. Comparative in vitro activity and clinical pharmacology of ticarcillin and carbenicillin. Antimicrob Agents Chemother. 1975 Oct;8(4):457–462. doi: 10.1128/aac.8.4.457. [DOI] [PMC free article] [PubMed] [Google Scholar]
  13. Parry M. F., Neu H. C. Pharmacokinetics of ticarcillin in patients with abnormal renal function. J Infect Dis. 1976 Jan;133(1):46–49. doi: 10.1093/infdis/133.1.46. [DOI] [PubMed] [Google Scholar]
  14. Patel I. H., Bornemann L. D., Brocks V. M., Fang L. S., Tolkoff-Rubin N. E., Rubin R. H. Pharmacokinetics of intravenous amdinocillin in healthy subjects and patients with renal insufficiency. Antimicrob Agents Chemother. 1985 Jul;28(1):46–50. doi: 10.1128/aac.28.1.46. [DOI] [PMC free article] [PubMed] [Google Scholar]
  15. Riggs D. S., Guarnieri J. A., Addelman S. Fitting straight lines when both variables are subject to error. Life Sci. 1978 Apr 3;22(13-15):1305–1360. doi: 10.1016/0024-3205(78)90098-x. [DOI] [PubMed] [Google Scholar]
  16. Rocci M. L., Jr, Jusko W. J. LAGRAN program for area and moments in pharmacokinetic analysis. Comput Programs Biomed. 1983 Jun;16(3):203–216. doi: 10.1016/0010-468x(83)90082-x. [DOI] [PubMed] [Google Scholar]
  17. Roselle G. A., Bode R., Hamilton B., Bibler M., Sullivan R., Douce R., Staneck J. L., Bullock W. E. Clinical trial of the efficacy and safety of ticarcillin and clavulanic acid. Antimicrob Agents Chemother. 1985 Mar;27(3):291–296. doi: 10.1128/aac.27.3.291. [DOI] [PMC free article] [PubMed] [Google Scholar]
  18. Sutherland R., Beale A. S., Boon R. J., Griffin K. E., Slocombe B., Stokes D. H., White A. R. Antibacterial activity of ticarcillin in the presence of clavulanate potassium. Am J Med. 1985 Nov 29;79(5B):13–24. doi: 10.1016/0002-9343(85)90124-x. [DOI] [PubMed] [Google Scholar]
  19. White A. R., Stokes D. H., Slocombe B., Sutherland R. Bactericidal effects of amoxycillin/clavulanic acid and ticarcillin/clavulanic acid in in-vitro kinetic models. J Antimicrob Chemother. 1985 Jan;15 (Suppl A):227–232. doi: 10.1093/jac/15.suppl_a.227. [DOI] [PubMed] [Google Scholar]

Articles from Antimicrobial Agents and Chemotherapy are provided here courtesy of American Society for Microbiology (ASM)

RESOURCES